1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Shine-On BioMedical Co.,Ltd.

Shine-On BioMedical Co.,Ltd.

6926.TWO
Shine-On BioMedical Co.,Ltd.TW flagTaipei Exchange
65.00
TWD
+0.20
- -
3.24BMarket Cap
Shine-On BioMedical Co.,Ltd.
6926.TWO
(Taipei Exchange)

Recent

price

65.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
0.19
- -
- -
Revenue per Share
- -
- -
-0.46
-0.43
-0.75
-2.39
- -
Basic EPS, GAAP
- -
- -
-0.5
-0.54
-0.55
-1.85
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
22.82
10.35
8.69
6.31
- -
Book Value per Share
- -
- -
49.06
25.77
22.75
20.38
- -
Tangible Book Value per Share
- -
43
18
45
50
50
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
10
- -
30
Sales/Revenue/Turnover
- -
- -
- -
- -
-658.16
- -
-418.33
Operating Margin (%)
- -
- -
1
2
2
2
2
Depreciation Expense
- -
- -
-8
-20
-37
-119
-110
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-390.22
- -
-367.62
Profit Margin (%)
- -
- -
904
1,166
1,130
1,012
892
Working Capital
- -
- -
2
1
- -
1
- -
LT Debt
- -
- -
908
1,174
1,136
1,018
907
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-4
-4.38
-8.23
-31.84
-42.61
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-10.84%
Free Cash Flow
- -
- -
25.78%
Net Income, GAAP
- -
- -
-7.24%
Sales/Revenue/Turnover
- -
- -
214.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
10
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
30

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.75
2024
- -
- -
- -
- -
-2.39
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Prestige BioPharma Limited (950210.KS)
Coya Therapeutics, Inc. (COYA)
4D pharma plc (DDDD.L)
Biostage, Inc. (BSTG)
Arch Therapeutics, Inc. (ARTH)
AEON Biopharma, Inc. (AEON)
Business
Shine-On BioMedical Co., Ltd. (6926.TWO) researches, develops, and manufactures anti-cancer new drug products, focusing on antibody therapeutics and nucleic acid drugs delivered via exosomes. The company offers trispecific T cell engaging nanobody (SOA101), EphA10 trispecific antibody engaging immune cells (SOA201), iNb intrabody nanoscale intracellular specific antibody drug (SOA102), iNb STAR TriTE T cell receptor nanoscale trispecific antibody drug (SOA103); and nucleic acid drugs including exosome-carrying nucleic acid and chemotherapy drugs (SOB101). Founded in April 2021 by Dr. Chiu-Chin Huang and headquartered at 5/F-6, 633 Section 2, Taiwan Boulevard, Taichung, Taiwan, it listed on the Emerging Stock Market of the Taipei Exchange in November 2022 and employs 22 staff targeting oncology indications such as solid tumors, ovarian cancer, and glioblastoma primarily in Taiwan. Shine-On BioMedical leverages two patented platforms: Tri-Specific Antibody with T-cell Engager technology and Targeted Exosome for Drug Delivery, with SOA101 advancing to Phase 1/2 clinical trials for locally advanced malignant solid neoplasms and recruiting patients. Recently, the company licensed its patented exosome small-molecule drug loading technology to ESCO Aster; founder Chiu-Chin Huang received the New Academy Member honor from the Industrial Technology Research Institute's Industry Academy; and it continues preclinical development of SOB-101 and SOB-102 alongside pipeline expansion.